Author: Avinash Gurbaxani (United Arab Emirates)
Co-authors: Insaf Saffar, Igor Kozak, Ammar Safar, Prasan Rao, Amal Masalmeh, Mohamed Farghaly
To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular-age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirates (UAE).
This was a retrospective, non-comparative, non-randomized, observational cohort analysis of the Dubai Real-world Claims Database (DRWD) with a 360-day follow-up period.
Adult patients diagnosed with nAMD or DME treated with ranibizumab or aflibercept for the first time were included. The primary objective was to evaluate anti-VEGF treatment patterns with respect to the proportion of patients receiving ranibizumab and aflibercept for nAMD and DME separately.
Of the 451 patients included in the final study cohort, 83.6% of patients at baseline had a diagnosis of DME (ranibizumab: 48.5%, aflibercept: 51.5%), and and 16.4% had a diagnosis of nAMD (ranibizumab: 40.5%, aflibercept: 59.5%), . Average treatment frequency of ranibizumab/aflibercept was similar for nAMD (mean 2.4/2.9 injections; P=0.2389) with fewer injections in the ranibizumab cohort for DME (mean: 1.9/2.5 injections; P=0.0002). The majority of patients received ≤3 anti-VEGF injections during the 360-day follow-up. The time between consecutive treatments was large (nAMD: 73.6 days/10.5 weeks; DME: 80.5 days/11.5 weeks). About (10-13.5%) of nAMD and DME patients switched their anti-VEGF therapy. The majority (83.8%) of patients in the study had a diabetes diagnosis during the follow-up period.
This real-world study provides an initial understanding of anti-VEGF treatment patterns in patients with nAMD and DME in the UAE. Treatment frequency of the 2 anti-VEGF agents assessed was similar in both patient populations. Both treatments were infrequently administered, with large dosing intervals.
Speaker fees from and advisory board member for Allergan, Bayer, Novartis